COVID-19 vaccination coverage in patients with chronic obstructive pulmonary disease – A cross-sectional study in Hungary

Fekete, Mónika; Horváth, Alpár; Santa, Balazs; Tomisa, Gábor; Szöllösi, Gergő József; Ungvári, Zoltán; Fazekas-Pongor, Vince; Major, David C.; Tarantini, Stefano; Varga, János

doi:10.1016/j.vaccine.2022.11.020

Cited by 12 publications

(22 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…16 [11][12][13][14][15][16][17][18][19][20][21] vs. 14 [10-19], P<0.001, modified Medical Research Council (mMRC) dyspnea scale: 2 [2-2] vs. 2 [1-2], P=0.01 and in the number of moderate exacerbations: 1 [0-1] vs. 0 [0-1], P=0.04. In addition, who did not take the third vaccination significantly more people were hospitalized for acute severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (16 vs. 0, P<0.001) and almost the same proportion (n=14) required pulmonary outpatient rehabilitation for post-COVID symptoms.…”

Section: Methodsmentioning

confidence: 99%

“…Anthropometric measurements, respiratory function test results, COVID infection history and post-COVID symptoms were recorded for the visiting patients. Our current study protocol and details of the conduct of the study were described in detail in our previous article (19).…”

Section: Study Design and Populationmentioning

confidence: 99%

“…Among the comorbidities the presence of hypertension (P=0.04) and acute myocardial infarction (MI) (P=0.008) were significantly associated with first booster vaccine uptake (Table 2). The quality of life: CAT: 16 [11][12][13][14][15][16][17][18][19][20][21] vs. 14 [10][11][12][13][14][15][16][17][18][19], P <0.001, mMRC dyspnoea scale points: 2 [2-2] vs. 2 [1-2], P=0.01, the severity of the disease (GOLD stage) and the number of moderate exacerbations in the previous year: 1 [0-1] vs. 0 [0-1], P=0.04 were also significantly associated with the uptake of the 3rd COVID-19 vaccination (Table 1). None of the three vaccine recipients had developed COVID-19 acute infection, while 11.46% of those who did not receive the first booster vaccination developed one (P<0.001).…”

Section: Co-morbidities Quality Of Life Acute Sars-cov-2 Infection An...mentioning

confidence: 99%

“…The coronavirus disease 2019 (COVID- 19) is an acute respiratory infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is currently causing a pandemic (1). Slowing the spread of the global epidemic remains a paramount importance to everyone, with many segments of society working to reduce the number of new infections (2).…”

Section: Introductionmentioning

confidence: 99%

“…The uptake rate of the COVID-19 first booster vaccine during the study period was 62.45%. Comparing patients who received the 3rd vaccine with those who did not receive the 3rd vaccine, the difference was significant in quality of life: COPD Assessment Test (CAT):16 [11][12][13][14][15][16][17][18][19][20][21] vs. 14 [10-19], P<0.001, modified Medical Research Council (mMRC) dyspnea scale: 2 [2-2] vs. 2 [1-2], P=0.01 and in the number of moderate exacerbations: 1 [0-1] vs. 0 [0-1], P=0.04. In addition, who did not take the third vaccination significantly more people were hospitalized for acute severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (16 vs. 0, P<0.001) and almost the same proportion (n=14) required pulmonary outpatient rehabilitation for post-COVID symptoms.…”

mentioning

confidence: 99%

See 4 more Smart Citations

First booster dose uptake of COVID-19 vaccine and disease-related factors in chronic obstructive pulmonary disease—a cross-sectional survey in Hungary

Fekete¹,

Horváth²,

Santa³

et al. 2023

Ann Palliat Med

View full text Add to dashboard Cite

Background: In chronic obstructive pulmonary disease (COPD), uptake of the coronavirus disease 2019 (COVID-19) booster vaccine is important, as they are more likely to develop serious complications. Our aim was to investigate the uptake rate of first booster vaccination against COVID-19 among COPD patients and to identify other related factors of vaccine uptake. Methods: We conducted a multicenter survey of COPD patients in Hungary by region: eastern, western and central ones from 15 November 2021. Respiratory function test results, anthropometric data and vaccination status were recorded for 1510 randomly selected patients over 35 years of age. Multiple logistic regression analysis was used to determine factors associated with uptake of COVID-19 first booster dose vaccines.Results: The average age was 67 [61-72] years, for men it was: 67 [62-73] and 66 [60-72] years for women, with a sample of 47.95% men and 52.05% women. The uptake rate of the COVID-19 first booster vaccine during the study period was 62.45%. Comparing patients who received the 3rd vaccine with those who did not receive the 3rd vaccine, the difference was significant in quality of life: COPD Assessment Test (CAT):16 [11][12][13][14][15][16][17][18][19][20][21] vs. 14 [10-19], P<0.001, modified Medical Research Council (mMRC) dyspnea scale: 2 [2-2] vs. 2 [1-2], P=0.01 and in the number of moderate exacerbations: 1 [0-1] vs. 0 [0-1], P=0.04. In addition, who did not take the third vaccination significantly more people were hospitalized for acute severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (16 vs. 0, P<0.001) and almost the same proportion (n=14) required pulmonary outpatient rehabilitation for post-COVID symptoms. The factors that were most associated with higher COVID-19 vaccine first booster dose uptake were older age [odds ratio (OR): 1.06; 95% confidence interval (CI): 1.04-1.08], male gender (OR: 0.74; 95% CI: 0.57-0.96), absence of previous COVID-19 infection (OR: 0.34; 95% CI: 0.23-0.51). Conclusions:The uptake rate of the COVID-19 booster vaccine among COPD patients in Hungary is lower than the target, and is associated with disease-related factors, and age, sex, previous COVID infection.The global COVID-19 vaccination target is 70% and 100% for elderly, vulnerable patients. Highlighting the importance of taking booster vaccine(s) should be a priority for health workers.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Study Design and Populationmentioning

confidence: 99%

Section: Co-morbidities Quality Of Life Acute Sars-cov-2 Infection An...mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

First booster dose uptake of COVID-19 vaccine and disease-related factors in chronic obstructive pulmonary disease—a cross-sectional survey in Hungary

Fekete¹,

Horváth²,

Santa³

et al. 2023

Ann Palliat Med

View full text Add to dashboard Cite

show abstract

Factors influencing individual vaccine preferences for COVID‐19 in the Sunyani Municipality, Ghana: An observational study using discrete choice experiment analysis

Gyasi,

Kumi,

Kwofie

2024

Health Science Reports

View full text Add to dashboard Cite

Background and AimsThere has been hesitancy among people with regard to accepting vaccines, especially that of coronavirus disease‐2019 (COVID‐19). This hesitancy is aggravated by the different vaccine alternatives available and what one considers before choosing a particular vaccine. The aim of this article was to investigate some driving factors that can influence an individual's COVID‐19 vaccine preference in the presence of other alternatives, using some specific vaccine characteristics.MethodsDiscrete choice questionnaire was designed using the attributes and their corresponding levels to collect data on participants' preference for a COVID vaccine over a period of 12 Weeks in Sunyani, Ghana, with the help of an observational study design. A total of 150 participants receiving Covid‐19 vaccines at the University of Energy and Natural Resources Hospital were systematically selected and interviewed. Factors considered included: Efficacy of the vaccine, credibility of the manufacturing company, side effects of the vaccine, and availability of the vaccine. Data was analyzed using the conditional probit of the discrete choice experiment (DCE).ResultsResults from the study using the conditional probit of the discrete choice experiment (DCE) showed efficacy, side effects, and availability as significant attributes for preference. However, there was no preference with respect to the credibility of the manufacturing company. In addition, vaccine availability was not a dis‐utility in comparison to the alternatives that are readily available. This disutility was however higher among males than females.ConclusionFrom the study, most respondents preferred a COVID‐19 vaccine that is highly efficacious or a vaccine with milder side effect or a vaccine that may not necessarily be readily available. It was also observed that dis‐utility is higher among males when it comes to vaccine not being readily available than females as the odds of a female choosing a vaccine that is readily available is much higher compared to their males counterparts.

show abstract

WITHDRAWN: COVID-19: Post infection implications in different age groups, mechanism, diagnosis, effective prevention, treatment, and recommendations

Raheem,

Rahim,

Gul

et al. 2024

Life Sciences

View full text Add to dashboard Cite

COVID-19 vaccination coverage in patients with chronic obstructive pulmonary disease – A cross-sectional study in Hungary

Cited by 12 publications

References 41 publications

First booster dose uptake of COVID-19 vaccine and disease-related factors in chronic obstructive pulmonary disease—a cross-sectional survey in Hungary

First booster dose uptake of COVID-19 vaccine and disease-related factors in chronic obstructive pulmonary disease—a cross-sectional survey in Hungary

Factors influencing individual vaccine preferences for COVID‐19 in the Sunyani Municipality, Ghana: An observational study using discrete choice experiment analysis

WITHDRAWN: COVID-19: Post infection implications in different age groups, mechanism, diagnosis, effective prevention, treatment, and recommendations

Contact Info

Product

Resources

About